盐酸沙格雷酯治疗下肢动脉硬化闭塞症的疗效观察

目的:研究盐酸沙格雷酯对下肢动脉硬化闭塞症(ASO)患者的疗效。方法:ASO患者分为盐酸沙格雷酯治疗组(n=46)和对照组(n=42)。治疗组口服盐酸沙格雷酯、阿司匹林,对照组仅口服阿司匹林。每例患者口服阿司匹林100mg/d,盐酸沙格雷酯100mg,3次/d,服用130d。观察患者的临床表现、Rutherford分型、踝肱指数(ABI)和药物不良反应。结果:治疗组患者感觉疼痛改善,步行距离增加,Rutherford分型0级和I级患者的改善具有显著性差异(P<0.05,P<0.01)。治疗后间歇性跛行从56.6%降低为28.3%,跛行距离显著延长(116.3±72.3m vs 243.5±175.3m,P<0.01),ABI指数显著改善(0.74±0.17 vs 0.86±0.18,P<0.01)。结论:盐酸沙格雷酯对ASO患者有明显的治疗作用。

Effect of sarpogrelate hydrochloride for patients with atherosclerotic obliterans of legs

Objecive:To evaluate the effect of sarpogrelate hydrochloride(anplag)for patients with atherosclerotic obliterans(ASO)of legs.Methods:The patients with ASO of legs were divided into sarpogrelate hydrochloride group(n=46)and control group(n=42).The patients in sarpogrelate hydrochloride group received sarpogrelate hydrochloride(100mg,tid)and aspirin(100mg,qd),whereas the patients in control group were administered aspirin(100mg,qd)only.The average therapeutic course was 130 days.Clinical manifestation,Rutherford type and ankle brachial index(ABI)were studied.Results:In comparison with control group,the severity of pain,Rutherford type 0 and 1 were improved with statistic significance(P<0.05,P<0.01).Incidence of patients with claudication decreased from 56.6% before treatment to 28.3% after treatment;claudication distance was prolonged(P<0.01);ABI were improved(0.74±0.17vs0.86±0.18,P<0.01).Conclusion:Anplag has therapeutic effect for patients with ASO of legs.